Taiwan's expertise in genetic engineering technology is between five and 10 years' behind the capabilities currently achieved by countries such as the USA, the UK, Germany, Japan, France, Switzerland and the Netherlands, according to a report published by the government-funded Development Center of Biotechnology.
Taiwan's expertise in cell, protein and biochemical engineering is even further behind, at about 10 years, according to the study. However, it forecasts that if a boost is given to research and development, the gap between Taiwan and the advanced countries in genetic engineering capability could be reduced to as little as two to five years after 1996, and that Taiwan could even catch these countries up by 2002.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze